Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01404
|
|||||
Drug Name |
Ximelagatran
|
|||||
Synonyms |
Exanta; Exarta; H 376/95; Ximelagatran [USAN:INN]; 192939-46-1; H 376-95; H 37695; Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-, ethyl ester; NCGC00183598-01; Ethyl (((1R)-1-cyclohexyl-2-((2S)-2-((4-(hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl-2-oxoethyl)amino)acetate; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ethyl ester; H 376 95; Exanta (TN); Exarta (TN); Xi-melagatran; H-376/95; Ximelagatran (JAN/USAN/INN); Glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester; Glycine, N-((1R)-1-cyclohexyl-2-((2S)-2-((((4-((hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)-2-oxoethyl)-, ester ester; H376/95
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Discovery agent [ICD11: N.A.] | Withdrawn | [1] | |||
Therapeutic Class |
Anticoagulants
|
|||||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C24H35N5O5
|
|||||
Canonical SMILES |
CCOC(=O)CNC(C1CCCCC1)C(=O)N2CCC2C(=O)NCC3=CC=C(C=C3)C(=NO)N
|
|||||
InChI |
InChI=1S/C24H35N5O5/c1-2-34-20(30)15-26-21(17-6-4-3-5-7-17)24(32)29-13-12-19(29)23(31)27-14-16-8-10-18(11-9-16)22(25)28-33/h8-11,17,19,21,26,33H,2-7,12-15H2,1H3,(H2,25,28)(H,27,31)/t19-,21+/m0/s1
|
|||||
InChIKey |
ZXIBCJHYVWYIKI-PZJWPPBQSA-N
|
|||||
CAS Number |
CAS 192939-46-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 473.6 | Topological Polar Surface Area | 146 | ||
Heavy Atom Count | 34 | Rotatable Bond Count | 11 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | |||
XLogP |
2.2
|
|||||
PubChem CID | ||||||
PubChem SID |
7849043
, 12015148
, 14785299
, 14858738
, 14883129
, 14883130
, 23997623
, 44712163
, 46509040
, 49973459
, 57372958
, 79267685
, 87225336
, 124894453
, 134338458
, 135106952
, 137002923
, 137726685
, 140950577
, 142578696
, 144207182
, 160645186
, 160967831
, 164235510
, 164766173
, 180370510
, 226396762
, 226396763
, 233586233
, 251971104
|
|||||
ChEBI ID |
CHEBI:65172
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT00206063) Long Term Open Follow-up With H376/95 vs. Warfarin. U.S. National Institutes of Health. | |||||
2 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.